Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Immunogenicity and Safety of Vaccination Against Tick Borne Encephalitis (TBE) in Patients Living With Multiple Sclerosis (MS) (MS and TBE vac)

17 de noviembre de 2026 actualizado por: Insel Gruppe AG, University Hospital Bern

This is a monocenter, prospective cohort study. The study investigates the response of patients living with multiple sclerosis (MS) to vaccination against tick-borne viral encephalitis (TBE).

The prevalence of TBE has increased significantly in Switzerland over the past two decades. Whereas previously only the lowland regions of northern Switzerland and the Aare Valley were considered areas where TBE vaccination was indicated, the disease is now endemic throughout Switzerland (except for Ticino). Since TBE specifically affects the nervous system, there is a clear indication for vaccination, particularly for people whose nervous system is already compromised.

MS is the most common neurological autoimmune disease among young adults in northern latitudes. It is a progressive disease characterized by a gradual deterioration of neurological functions. The course of the disease can be slowed through immunomodulatory therapies. However, these therapies also lead to a certain degree of immunosuppression, which may reduce the immune response to vaccinations. At the same time, some people with MS experience fear or scepticism towards vaccinations, as infections often lead to a worsening of symptoms or can trigger a relapse. Since vaccinations mimic an infection to some extent, this concern is sometimes transferred to vaccinations as well.

The study hypothesizes that the TBE vaccine in people living with MS on non-B-cell depleting treatment shows adequate immunogenicity.

Moreover, the study will assess the safety of TBE vaccination.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Tipo de estudio

De observación

Inscripción (Estimado)

50

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: Robert Hoepner, Prof. Dr. med.
  • Número de teléfono: +41 316325835
  • Correo electrónico: robert.hoepner@insel.ch

Ubicaciones de estudio

      • Bern, Suiza, 3010
        • Reclutamiento
        • University Hospital of Bern
        • Contacto:
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

The investigators target a sample size of 50 people living with MS with stable RRMS (no evidence of disease activity -NEDA-3 status - as defined by no clinical relapse, no EDSS worsening and no new MS-lesions on MRI) for ≥ 1 year prior to inclusion into the study and treated with non-B-cell depleting therapies for at least 6 months in monotherapy.

In order to have a homogenous and stable patient population, the investigators decided to include only patients without evidence of disease activity for at least 1 year prior to inclusion. Considering the latter the investigators classify any disease reactivation during the period of 42 days (+/- 7days) after the first dose / booster dose as related to the intervention (vaccination).

Descripción

Inclusion Criteria

  • Adult (≥ 18 years old)

  • Suspected neuroimmunological disorder with CNS affection

    • including suspicion of Multiple Sclerosis (MS)
    • Diagnosed Multiple Sclerosis (MS)
    • Clinically Isolated Syndrome
    • Radiologically Isolated Syndrome
  • stable RRMS - defined as no evidence of disease activity-NEDA-3 status-as defined by no clinical relapse, no EDSS worsening and no new MS-lesions on MRI for ≥ 1 year prior to inclusion

  • treated with non-B-cell depleting therapies for at least 6 months in monotherapy

  • TBE vaccine:

    • never been vaccinated against TBE or
    • clinical indication for booster vaccination (person living with MS and has had primary series of 3 vaccines of which the last one was ≥ 10 years ago)
  • Provided written informed consent

Exclusion Criteria

  • Any B-cell depleting therapies in last 12 months prior to recruitment
  • Any other vaccination in last 2 months prior to recruitment
  • Any foreseeable and necessary other vaccination up to 42 days post dose 1
  • Immunoglobulin-Infusion (intravenous or subcutaneous, IVIG or SCIG) in the last 4 months prior to the drawing of study samples

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Primary vaccination series or Booser against TBE in patients with MS

According to Swiss guidelines, patients with MS will receive the primary vaccination series (3 doses) against TBE (if they have never been vaccinated) or a TBE booster (if they have already received the primary vaccination series and their last vaccination was ≥ 10 years ago).

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Primary immunogenicity endpoint
Periodo de tiempo: 42 days post dose 1

Change in antibody concentration (GMC) from baseline to day 42 post dose 1 as measured by ELISA

42 days post dose 1

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Immunogenicity endpoint
Periodo de tiempo: 42 days post dose 1

Change in antibody titers as measured by serum neutralizing test (SNT) from baseline to day 42 (post dose 1)

42 days post dose 1
Immunogenicity endpoint
Periodo de tiempo: 7 months post dose 1 or 6 months post booster dose

Change in antibody titers as measured by ELISA from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose.

7 months post dose 1 or 6 months post booster dose
Immunogenicity endpoint
Periodo de tiempo: 7 months post dose 1 or 6 months post booster dose

Change in antibody titers as measured by SNT from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose.

7 months post dose 1 or 6 months post booster dose
Immunogenicity endpoint
Periodo de tiempo: at each time point (7 months)

Seropositivity as measured by ELISA . Seropositivity is defined as IgG antibody concentration >150 U/ml for ELISA.

at each time point (7 months)
Immunogenicity endpoint
Periodo de tiempo: at each time point (7 months)

Seropositivity as measured by SNT at each time point. Seropositivity is defined as antibody titer >1:10 for SNT.

at each time point (7 months)
Safety endpoint
Periodo de tiempo: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Incidence of MS-relapses - defined clinically, according to clinical expert judgement, by the presence of MS-typical symptoms with objectifiable findings lasting more than 24 hours, without fever or infection.

42 (+/-7d) post dose 1
Safety endpoint
Periodo de tiempo: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Activity in cerebral MRI scan (new or enlarging lesions or gadolinium uptake)

42 (+/-7d) post dose 1
Safety endpoint
Periodo de tiempo: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Neurological assessment (EDSS)

42 (+/-7d) post dose 1
Safety endpoint
Periodo de tiempo: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Multivariable blood biomarker based scores for MS disease activity (MSDA) and disease pathways (Octave Bioscience, USA)

42 (+/-7d) post dose 1
Safety endpoint
Periodo de tiempo: 42 (+/-7d) post dose 1

The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1

- Vaccine reactogenicity (solicited and unsolicited local and systemic vaccine reactions)

42 (+/-7d) post dose 1

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

22 de abril de 2026

Finalización primaria (Estimado)

31 de mayo de 2027

Finalización del estudio (Estimado)

31 de mayo de 2027

Fechas de registro del estudio

Enviado por primera vez

28 de agosto de 2026

Primero enviado que cumplió con los criterios de control de calidad

17 de noviembre de 2026

Publicado por primera vez (Actual)

19 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

17 de noviembre de 2026

Última verificación

1 de junio de 2026

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir